期刊文献+

老年2型糖尿病患者骨质疏松症的危险因素分析 被引量:5

Analysis of risk factors of osteoporosis in elderly patients with type 2 diabetes
下载PDF
导出
摘要 目的探讨老年2型糖尿病患者骨质疏松症(0P)的危险因素。方法选取我院老年病科2012年12月~2013年12月门诊及住院的老年2型糖尿病患者192例,分为OP组(A组)和非OP组的(B组)。收集患者的一般临床资料及实验室检查结果,运用t检验对两组一般资料进行比较,并对相关危险因素进行Logistic回归分析。结果(1)两组HbAIC(糖化血红蛋白A1C)、FINS(空腹胰岛素)、FBG(空腹血糖)、BMI(体重指数)差异有统计学意义(P〈0.05);Ca^2+(血钙)、P(血磷)比较差异无统计学意义(P〉0.05)。(2)HbA1C、FINS水平、病程、BMI是老年2型糖尿病患者OP的独立危险因素(P〈0.05)。结论积极控制血糖、保护胰岛功能、维持理想体重,对于老年2型糖尿病患者预防骨质疏松症具有重要参考价值。 Objective To investigate the risk factors of osteoporosis (OP) in elderly patients with type 2 diabetes. Methods 192 elderly outpatients and inpatients with type 2 diabetes treated in the geriatric department of our hospital from December 2012 to December 2013 were selected and divided into the OP group (group A) and the non-OP group (group B). The patients' ordinary clinical data and laboratory inspection results were collected. The ordinary data of the two groups were compared using t test and relevant risk factors were analyzed using Logistic regression analysis. Results (1) The two groups were statistically different in HbA1C (glycosylated hemoglobin A1C), FINS(fasting insulin), FBG (fasting blood glucose) and BMI (body mass index)(P 〈 0.05). (2) HbA1C, FINS level, course of disease and BMI were independent risk factors of OP in elderly patients with type 2 diabetes(P 〈 0.05). Conclusion Active control of blood sugar, protection of insulin function and maintenance of ideal body weight are of important reference value for the prevention of osteoporosis in elderly patients with type 2 diabetes.
出处 《中国医药科学》 2014年第11期53-55,共3页 China Medicine And Pharmacy
关键词 2型糖尿病 老年 骨质疏松症 危险因素 Type 2 diabetes Elderly Osteoporosis Risk factors
  • 相关文献

参考文献20

  • 1《中国糖尿病防治指南》正式出版[J].中华糖尿病杂志(1006-6187),2005,13(4):249-249. 被引量:5
  • 2何涛,杨定焯,刘忠厚.骨质疏松症诊断标准的探讨[J].中国骨质疏松杂志,2010,16(2):151-156. 被引量:90
  • 3Montagnani A, Gonnelli S, Alessandri M, et al.Osteoporosis and risk of fracture in patients with diabetes: an update[J]. Aging Clin Exp Res,2011,23 ( 2 ) : 84-90.
  • 4Kumeda Y, Inaba M, Nishizawa Y.Secondary osteoporosis and its treatment: diabetes mellitus[J].Nippon Rinsho, 1998,56: 1579-1586.
  • 5王君,舒仪琼.2型糖尿病骨质疏松症发病机制研究进展[J].中医药临床杂志,2012,24(2):183-184. 被引量:23
  • 6Rocha M, Nava LE, Vazquez de la Torre C, et al.Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial[J].J Periodontol,2001,72 ( 2 ) : 204-209.
  • 7Barrett-Connor E, Ensrud KE, Harper K, et al.Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation ( MORE ) trial on the effects of three years of raloxifene treatment on glyeemie control and cardiovascular disease risk factors in women with an without type 2 diabetes[J].Clin Ther, 2003,25 ( 3 ) : 919-930.
  • 8Elena Ceearelli, Elisa G.Guarino, Daniela Merlotti, et al. Beyond Glyeemie Control in Diabetes Mellitus: Effects of lneretin-Based Therapies on Bone Metabolism [J]. Front Endocrinol ( Lausanne ),2013,4 ( 13 ) : 73.
  • 9Tahrani AA, Ball A, Shepherd L, et al.The prevalenceof vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK[J].Int J Clin Pract, 2010,64 ( 5 ) : 351-355.
  • 10Lecka-Czemik B. Bone as a target of type 2 diabetes treatment[J].Curr Opin Investiq Drugs,2009,10 ( 10 ): 1085-1090.

二级参考文献88

共引文献207

同被引文献67

  • 1Bipradas Roy.Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures[J].World Journal of Diabetes,2013,4(4):101-113. 被引量:42
  • 2Johne11 O,Kanis JA. An estimate of the worldwide preva- lence and disability associated with osteoporotic fractures [J]. Osteoporos International, 2006,17(12) : 1726-1733.
  • 3Black DM,Thompson DE,Baure DC,et al. Fracture risk re- duction with alendranate in women with osteoporosis:The Fracture Intervention Trial [J]. J Chn Endocrinol Metab, 2000,85(11):4118-4124.
  • 4Patil S, Holt G,Raby N,et al. Prospective,double blind, randomized, controlled trial of simvastatin in human frac- ture healing [J]. Journal of Orthopaedic Research,2009, 27(3) :2812285.
  • 5Otmar R, Reventlow SD, Nieholson GC, et al. General medical practitioners" knowledge and beliefs about os- teoporosis and its investigation and management [J]. Arch Osteoporos, 2012,7 (1-2) : 107-114.
  • 6Wilting I, de Vries F, Thio B, et al. Lithium use and the risk of fractures [J]. Bone,2007,40(5) : 1252-1258.
  • 7Ha Guenauer D,Welch V,Shea B,et al. Fluoride for the treatment of postmenopausal osteoporotic fractures:a recta-analysis [J]. Osteoporosis International,2000,11 (9) : 727-738.
  • 8Lindsay R,Zhou H,Cosman F,et al. Effects of a one- month treatment with PTH (1- 34)on bone formation on cancellous,endocortical,and periosteal surfaces of the human ilium [J]. J Bone Miner Res,2007,22(14) :495-502.
  • 9Ciaschini PM, Straus SE, Dolovich LR, et al. Community based intervention to optimize osteoporosis management: randomized controlled trial [J]. BMC Geriatr,2010, (10) : 60.
  • 10Ciaschini PM, Straus SE, Dolovich LR, et al. Community- based randomised controlled trial evaluating falls and os- teoporosis risk management strategies [J]. Trials,2008, 9:62.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部